Skip to content

Mechanism of chondrocyte degeneration in knee osteoarthritis

Mechanism of chondrocyte degeneration in knee osteoarthritis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105687
Enrollment
Unknown
Registered
2025-07-09
Start date
2025-03-06
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Group 1:Do not engage in any exercise intervention and maintain the original lifestyle and daily activity habits. No new exercise guidance or dietary control intervention was received during the resea
Group 2:The exercise intensity is maintained at 60% - 75% of the individual's peak heart rate (HR_peak). It is accomplished using a power bicycle (Monark Ergometer)
Participants reached the target heart rate after the warm-up period and maintained this heart rate range throughout the exercise. The weekly training frequency and the total intervention period were 1
Group 3:Four 4-minute high-intensity intervals (85% - 95% HR_peak) and three 3-minute recovery intervals (60% - 70% HR_peak). The training was completed on the same equipment. Ensure that the energy c

Sponsors

The First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed with knee osteoarthritis, with the Kellgren-Lawrence grade of the affected knee confirmed by imaging as grade IV, or proposed to receive total knee arthroplasty (TKA) treatment after preoperative assessment; Or have symptoms related to knee osteoarthritis and meet the obesity diagnostic criteria (body mass index BMI >=28.0 kg/m², body fat percentage BFP >=30%), and have the ability to participate in exercise intervention experiments; 2. No serious neurological, cardiovascular, respiratory or mental system diseases, and passed the preoperative/pre-exercise safety screening assessment; 3. No glucocorticoid drug treatment was received within 3 months before the operation; 4. No history of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus; 5. No history of active infection or malignant tumor; 6. Be capable of cooperating to complete the process of biological sample collection or exercise intervention; 7. Understand the purpose and process of this study and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Diagnosed with autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus; 2. Within 3 months before the operation, received glucocorticoids, intra-articular injections or other treatments that might affect the research results; 3. Those with severe cardiovascular, neurological or mental system diseases who cannot tolerate exercise or surgery; 4. Have cognitive impairments, poor compliance, and are unable to complete the research process or cooperate with the follow-up. 5. Those with active infections or those who have recently undergone major joint surgery; 6. Other circumstances where the researcher deems it inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
weight;Height;Body composition;Kinematic function;Clinical score;

Secondary

MeasureTime frame
age;gender; Lipid profile;Blood glucose;Maximal oxygen uptake;Lung capacity;Lung function;

Countries

China

Contacts

Public ContactFu Ming

The First Affiliated Hospital of Sun Yat-sen University

guch8@mail2.sysu.edu.cn+86 132 2548 8054

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026